Science and Research

Metabolic dependency mapping identifies Peroxiredoxin 1 as a driver of resistance to ATM inhibition

Metabolic pathways fuel tumor progression and resistance to stress conditions including chemotherapeutic drugs, such as DNA damage response (DDR) inhibitors. Yet, significant gaps persist in how metabolic pathways confer resistance to DDR inhibition in cancer cells. Here, we employed a metabolism-focused CRISPR knockout screen and identified genetic vulnerabilities to DDR inhibitors. We unveiled Peroxiredoxin 1 (PRDX1) as a synthetic lethality partner with Ataxia Telangiectasia Mutated (ATM) kinase. Tumor cells depleted of PRDX1 displayed heightened sensitivity to ATM inhibition in vitro and in mice in a manner dependent on p53 status. Mechanistically, we discovered that the ribosomal protein RPL32 undergoes redox modification on active cysteine residues 91 and 96 upon ATM inhibition, promoting p53 stability and altered cell fitness. Our findings reveal a new pathway whereby RPL32 senses stress and induces p53 activation impairing tumor cell survival.

  • Li, H.
  • Furusawa, T.
  • Cavero, R.
  • Xiao, Y.
  • Chari, R.
  • Wu, X.
  • Sun, D.
  • Hartmann, O.
  • Dhall, A.
  • Holewinski, R.
  • Andresson, T.
  • Karim, B.
  • Villamor-Payà, M.
  • Gallardo, D.
  • Day, C. P.
  • Pal, L. R.
  • Nair, N. U.
  • Ruppin, E.
  • Aladjem, M. I.
  • Pommier, Y.
  • Diefenbacher, M. E.
  • Lim, J. M.
  • Levine, R. L.
  • Stracker, T. H.
  • Weyemi, U.

Keywords

  • ATM kinase
  • Disulfide stress
  • Peroxiredoxin 1
  • RPL32 redox modification
  • p53 activation
Publication details
DOI: 10.1016/j.redox.2025.103503
Journal: Redox Biol
Pages: 103503 
Work Type: Original
Location: CPC-M
Disease Area: LC
Partner / Member: HMGU
Access-Number: 39854937

DZL Engagements

chevron-down